MEI Pharma, Inc. (NASDAQ:MEIP) is expected to report fourth quarter earnings results, after market close, on Wednesday 9th September 2020.
Analysts polled by Thomson Reuters anticipate fourth quarter income of $ 0.21 per share.
Looking ahead, the full year loss are expected at $ 0.05 per share on the revenues of $ 48.42 million.
Previous Quarter Performance
MEI Pharma, Inc. reported loss for the third quarter of $ 0.11 per share, from the revenue of $ 1.24 million.
Stock Performance
Shares of MEI Pharma, Inc. traded up $ 0.14 or 5.69 percent on Tuesday, reaching $ 2.60 with volume of 671.60 thousand shares. MEI Pharma, Inc. has traded high as $ 2.66 and has cracked $ 2.38 on the downward trend
According to the previous trading day, closing price of $ 2.60, representing a 241.67 % increase from the 52 week low of $ 0.72 and a 44.84 % decrease over the 52 week high of $ 4.46.
The company has a market capital of $ 275.60 million and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
Conference Call
MEI Pharma, Inc. will be hosting a conference call at 5:00 PM eastern time on 9th September 2020, to discuss its 4Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.meipharma.com
MEI Pharma, Inc., a pharmaceutical company, focuses on the clinical development of novel therapies for the treatment of cancer. The companys clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer; and Voruciclib, an oral cyclin-dependent kinase inhibitor.
